Immunization with the 69-kD outer membrane protein (OMP) of Bordetella pertussis protected neonatal mice against lethal respiratory challenge with B. pertussis 18323. Active immunization elicited a serum IgG anti-69-kD OMP response at the time of challenge, with IgG anti-69-kD OMP antibodies detected in bronchoalveolar lavage fluid after challenge. Intravenous administration of BPE8, a monoclon...

Pertussis is increasingly recognized as a source of infection in adults who then commonly infect young children. Immunity to illness caused by Bordetella pertussis is not long-lived, so optimal control of pertussis may require booster immunizations. In a cost-benefit analysis, we evaluated the benefits of 7 independent strategies for administering a pertussis booster, in the form of a diphtheri...

an interference is observed between whooping-cough antigens and salk polioc vaccine even if the two components are mixed immediately before use. the phenomenon is more evident when flulid antigens are injected. pertussis soluble antigen, which gives a good serological response in rabbits, when used alone or combined with dt, is inactivated in the presence of salk polio vacc:ne

background: immunization against diphtheria, tetanus and pertussis (dtp) has long been applied in iran using whole cell vac­cine. despite the role of whole cell dtp (dtwp) vaccine in reduction of mortality as a result of disastrous diseases such as diphtheria, tetanus, and pertussis, serious local and systemic complications have been attributed to these vaccines. this study was performed to det...

TO THE EDITOR—Despite extensive vaccinations, whooping cough has resurged in industrial countries. The major explanations include wanning immunity associated with the acellular pertussis vaccines (ACVs) and Bordetella pertussis adaptation to vaccine-induced immunity. ACVs contain purified antigens in different combinations: pertussis toxin (Ptx), filamentous hemagglutin, pertactin (Prn), and fi...

BACKGROUND The Advisory Committee on Immunization Practices (ACIP) recommends the use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine for routine wound management in adolescents and adults who require a tetanus toxoid-containing vaccine who were vaccinated ≥ 5 years earlier with tetanus toxoid, reduced diphtheria toxoid (Td) vaccine, and who have not previou...

Efficacy of whole cell pertussis vaccines (wP) in humans correlates with (and hence is measured by) the ‘mouse protection test’, wherein vaccinated mice are challenged with live B. pertussis. This test does not work similarly with acellular pertussis vaccines (aP); hence antibody levels to various antigens are measured as a surrogate marker of efficacy. This difference between the direct as com...

A trial of the efficacy of a plain whole cell pertussis vaccine was conducted in Sweden. In this non-blinded trial 525 infants aged 2 months who were born on days with an even number received three doses of vaccine one month apart and 615 infants of the same age who were born on days with an odd number were enrolled as controls. During the 18 months of follow up there were 55 cases of pertussis...

The results of 9.5 years of official testing of vaccines containing pertussis vaccine, plain or adsorbed with alum, Al(OH)(3), or AlPO(4), are reported. Toxicity was evaluated by weight changes in mice at 3 and 7 days after injection and intercurrent deaths. Toxicity was encountered during the early use of AlPO(4) in pertussis vaccine products, with a special product and quadruple-antigen vacci...